With more than 35 years of experience, we are a leading expert in the conjugation of highly active molecules to monoclonal antibodies for the development and manufacture of antibody-drug conjugates (ADCs).
Antibody-drug conjugation technology uses monoclonal antibodies or other biologics to deliver highly potent active pharmaceutical ingredients (HPAPIs) to targeted cells. In conjugated form, the HPAPIs exhibit more selective therapeutic activity, sparing non-target cells from many of the toxic effects and improving the safety profile. Customers are quickly adapting these complex technologies and employing them to develop new oncology and non-oncology products that are more targeted and safer. Today, novel bioconjugates also feature diverse payloads (e.g. oligonucleotides, radionuclides, targeted small molecules and degraders) and antibody formats (e.g. bispecifics, fragments) to serve diverse applications and indications.
Interested in a certain contract manufacturing service or technology? Fill out the form below and we will provide you with the information you need.
Our comprehensive ADC solutions include analytical and process support throughout all stages of drug development and manufacture:
Our ChetoSensar™ technology can help to improve the solubility of ADCs and provides access to highly hydrophobic novel payloads that might not otherwise be considered.
Our extensive bioconjugation expertise shortens your path to the clinic through rapid production of development-grade ADC construct libraries with your antibody and/or linkers and payloads of choice for preclinical lead candidate selection.
Next to (cGMP) DM 1 - Mertansinoid, we offer a comprehensive product line of advanced intermediates for the most common payload classes aimed at significantly reducing the time, risks, and challenges associated with ADC payload development and manufacturing.
Our dedicated experts will listen to you at every step of your process to provide tailored guidance and solutions based on scientific knowledge, quality, and regulatory compliance for all your key milestones, no matter the scale of your operation.
From evaluation to execution, our highly skilled and dedicated project managers are responsible for coordinating multi-disciplinary teams, international site activities and timelines:
The ADC manufacturing facilities were purpose-built for handling HPAPIs, antibodies, linkers and for performing complex conjugation processes in cGMP suites featuring isolators and specialized handling equipment. Our innovative processing templates include single-use technology and advanced PAT for process control.
The global footprint of our contract manufacturing services assures you of a wide-ranging regulatory and supply expertise, easily accessed through a single trusted partner.
Biopharma development and manufacturing facility for mAbs production with over 25+ years of GMP experience. Including pilot, and GMP capabilities.
Our ADC & Bioconjugation manufacturing site. We offer more than 35 years of experience as the leading expert in the conjugation of HPAPI to mAbs for ADC manufacture.
Our API manufacturing site SafeBridge® certified facility. The world’s largest single nanogram containment facility in 2022.
Case Study: Complete Single-Use ADC Technology from Development
Through Scale-up
Flyer: Integrated ADC Services from Gene to BDS and from Pre-clinical to Commercial
Flyer: ChetoSensar: Consider it DisSolved
Flyer: Discover Comprehensive ADC Solutions
Flyer: ADC Express™ Pre-clinical Conjugation Services for the Best Candidate Selection
Flyer: Maytansinoid Products for Your Drug Conjugate Program
Flyer: Simplify Your Synthesis with ADCore™ Payload Intermediates
Commercializing Antibody-Drug Conjugates: a CMO’s Journey
White Paper: Use of Payload Core Compounds to Accelerate ADC Clinical Development Timelines
Webinar: The Evolution of ADC Manufacturing Expertise During the Last 10 Years
Webinar: Complete Single-use ADC Technology from Development Through Scale-up
Webinar: Commercializing Antibody-Drug Conjugates: a CMO’s Journey
Webinar: ChetoSensar™ Technology Platform: Consider it DisSolved
Webinar: How to Accelerate and Enhance ADC Therapies
To continue reading please sign in or create an account.
Don't Have An Account?